XOLAIR 150 MG / 1 ML
OMALIZUMAB : 150 MG / 1 ML · DIN 02459795 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is XOLAIR?
XOLAIR 150 MG / 1 ML contains OMALIZUMAB : 150 MG / 1 ML. It is listed in the Health Canada Drug Product Database under DIN 02459795, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 06-Jul-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XOLAIR used for?
Moderate to severe persistent allergic asthma (6+ years); Severe chronic rhinosinusitis with nasal polyps (adults); Chronic idiopathic urticaria (12+ years) symptomatic despite H1 antihistamines.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02459795 |
|---|---|
| Brand name | XOLAIR |
| Generic / active ingredient | OMALIZUMAB : 150 MG / 1 ML |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 150 MG / 1 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | R03DX05 OMALIZUMAB |
| AHFS class | 90:28.16.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Jul-2017 |
| Original market date | 2017-07-06 00:00:00 |
How is it administered?
75 to 600 mg SC every 2 or 4 weeks. Dose based on serum total IgE level and body weight for asthma/nasal polyps. For CIU, 150 or 300 mg every 4 weeks regardless of IgE/weight.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted solution: 2-8°C for up to 8 hours or 25°C for 2 hours. (Note: Full storage for unopened product not in snippet, but stability for reconstituted is provided).
How is it supplied?
150 mg single-use vial (lyophilized); Pre-filled syringes and pens in 75 mg/0.5 mL, 150 mg/1.0 mL, and 300 mg/2.0 mL strengths.
Contraindications
Known hypersensitivity to omalizumab or any component of the formulation, or previous severe hypersensitivity reaction to Xolair.
Warnings and precautions
Serious Warning: Anaphylaxis (life-threatening) can occur after any dose. Monitor patients in a healthcare setting. Risk of Churg-Strauss syndrome and malignant neoplasms.
What can be used instead?
Other Canadian products sharing ATC code R03DX05 OMALIZUMAB. 8 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OMLYCLO | 150 MG / 1 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02553813 |
| OMLYCLO | 75 MG / 0.5 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02553805 |
| XOLAIR | 150 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02260565 |
| XOLAIR | 150 MG / 1 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02545144 |
| XOLAIR | 300 MG / 2 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02545160 |
| XOLAIR | 75 MG / 0.5 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02545136 |
| XOLAIR | 75 MG / 0.5 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02459787 |
| XOLAIR | 300 MG / 2 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | APPROVED | DIN 02545152 |
Who else supplies OMALIZUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OMALIZUMAB appears in 806 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.